In ACHIEVE-1 , the first of seven Phase 3 studies in people with type 2 diabetes, orforglipron reduced A1C by an average of 1.3% to 1.6% across doses compared to placebo at 40 weeks, starting from a baseline of 8.0%
After a single injection of CJC-1295 in healthy adults, GH rises 2- to 10-fold and IGF-1 increases 1.5- to 3-fold over baseline for several days
Dietary adjustments like eating smaller, lower-fat meals and avoiding high-fiber foods during the titration phase can help distinguish medication effects from post-surgical symptoms and reduce overall discomfort
Hitting your protein target every day is non-negotiable
Immunity 22 , 507517 (2005)
The FDA does not review or approve compounded GLP-1 medications for safety, effectiveness, or quality